secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2026-09-03T12:00:31+00:00
Accession:  0001104659-26-104929
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track to Liquidia's YUTREPIA for SSc-Raynaud's phenomenon
-------------------------------------------------------------------------

- FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for systemic sclerosis-associated Raynaud's phenomenon (SSc-RP).
- No therapy is currently FDA-approved for SSc-RP; condition affects up to 90% of systemic sclerosis patients.
- Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in Q4 2026.
- Company estimates U.S. addressable population of ~30,000 moderate-to-severe SSc-RP patients.
- Fast Track enables more frequent FDA interactions and potential rolling review and Priority Review eligibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926104929/0001104659-26-104929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926104929/tm2624724d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-104929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer